Algernon Pharmaceuticals (XCNQ:AGN) Other Income (Expense) : C$1.91 Mil (TTM As of Feb. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Other Income (Expense)?

Algernon Pharmaceuticals's other income expense for the Algernon Pharmaceuticals's pretax income for the three months ended in Feb. 2025 was C$0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Feb. 2025 was C$1.91 Mil.

Algernon Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Algernon Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Other Income (Expense) Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Other Income (Expense)

Get a 7-Day Free Trial

0.09

0.31

-0.04

-1.54

1.91

Algernon Pharmaceuticals Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Other Income (Expense)	Get a 7-Day Free Trial															-	1.91	-	-	-

Algernon Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.91 Mil.

Algernon Pharmaceuticals (XCNQ:AGN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Executives

Christopher Moreau	Director, Senior Officer
Christopher Scott Bryan	Senior Officer
James Kinley	Senior Officer
Harry J.f. Bloomfield	Director
Rajpaul Attariwala	Director
Mark Williams	Director
Howard Gutman	Director
Michael Sadhra	Senior Officer
Kulwant Malhi	10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines